Skip to content
Politically.com Search all
Menu

2026 · 1st Quarter (Jan 1 - Mar 31)

EMERGENT BIOSOLUTIONS

Filed by THE NICKLES GROUP, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 15, 2026
Income
$40,000.00
Expenses
Not reported
Filing UUID
59b96ba1-7962-4274-a0d9-3f310e0475fd
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

HCR · Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, FY2027 NDAA provisions related to biological and chemical defense and access to naloxone.

DEF · Defense

National Defense Authorization Act for FY2027, provisions related to biological and chemical defense and access to naloxone.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.